Harvard Business Review

MAY 26, 2014

But ongoing changes in policy, technology, and industry culture are now creating unprecedented opportunities for those with just the right kind of crazy. billion in 2013, up 39% from 2012. Consumer technology offers direct access to patients. These technologies currently affect a small share of the population.

Health Care 8

Health Care Venture Funding Entrepreneur Pharmaceuticals 8

Harvard Business Review

AUGUST 23, 2012

These hurdles aren't unique to financial services — insurance, pharmaceuticals, health care and government all face regulation, to name a few examples. without any compliance process or technology in place.". Adopting technology that keeps pace with regulatory requirements is equally important.

Compliance 15

Compliance Media Compliance Officer Policies 15

Harvard Business Review

NOVEMBER 30, 2017

A few outlier industries (notably pharmaceuticals, medical devices, and computers) prop up the sector’s aggregate performance; most others have experienced flat growth or outright declines in real GDP over the past two decades. In some instances, the end results were firm closures and lost jobs.

Supply Chain 8

Supply Chain McKinsey Incentives Bottom-up 8

Harvard Business Review

OCTOBER 21, 2013

I found myself reflecting on this recently while speaking with two business leaders in one of the world’s great pharmaceutical companies. How likely was it that they would be on top of the rapid developments in Asian consumer markets, or in technology and design emanating from Silicon Valley? Leadership Managing uncertainty'

Drucker 8

Drucker Diversity Pharmaceuticals Uncertainty 8

Harvard Business Review

JANUARY 13, 2014

But for 2013 he was only about 15 percent on target. But his 2013 forecasts were certainly within the realm of the possible; they just failed to materialize this year. Companies in the pharmaceutical industry – particularly in the U.S. – Competition Managing uncertainty' Most years he is about 50 percent correct.

Uncertainty 8

Uncertainty Pharmaceuticals Industry Marketing 8

Harvard Business Review

MARCH 16, 2015

Please note that titles used here reflect the positions the individuals held in 2013, when we conducted the interviews for a separate article ). Talent Management. As a pharmaceutical company, we obviously were part of that whole ecosystem. Talent-related issues were the top concern, mentioned by 16 of the CEOs.

CEO 8

CEO Stephenson Pharmaceuticals Globalization 8

Harvard Business Review

FEBRUARY 11, 2016

Google and Intel rely on experts in social science and biomechanics to develop transformative products by better understanding how people think about and use technology. In 2013, Accenture suggested that 20 to 30 percent of the total workforce falls outside the organization’s traditional full-time, permanent employment relationship.

Agility 8

Agility Organization Resources Bureaucracy 8